Abstract Aims: Activation of the NAD + dependent protein deacetylase SIRT1 has been proposed as a therapeutic strategy to treat mitochondrial dysfunction and insulin resistance in skeletal muscle. However, lifelong overexpression of SIRT1 in skeletal muscle does not improve parameters of mitochondrial function and insulin sensitivity. In this study, we investigated whether temporal overexpression of SIRT1 in muscle of adult mice would affect skeletal muscle mitochondrial function and insulin sensitivity. Methods: To circumvent potential effects of germline SIRT1 overexpression, we utilized an inducible model of SIRT1 overexpression in skeletal muscle of adult mice (i-mOX). Insulin sensitivity was assessed by 2-deoxyglucose uptake, muscle maximal respiratory function by high-resolution respirometry and systemic energy expenditure was assessed by whole body calorimetry. Results: Although SIRT1 was highly, and specifically, overexpressed in skeletal muscle of i-mOX compared to WT mice, glucose tolerance and skeletal muscle insulin sensitivity were comparable between genotypes. Additionally, markers of mitochondrial biogenesis, muscle maximal respiratory function and whole-body oxygen consumption were also unaffected by SIRT1 overexpression. Conclusion: These results support previous work demonstrating that induction of SIRT1 in skeletal muscle, either at birth or in adulthood, does not impact muscle insulin action or mitochondrial function.
Interestingly, in this mOX model we found no effects on muscle insulin sensitivity, maximal mitochondrial respiration or whole body metabolic rate in chow-or high fat diet-fed mice. 10, 11 This contrasts with a number of studies demonstrating that treatment of adult rodents with small molecule activators of SIRT1 enhances muscle insulin sensitivity and respiratory capacity. [7] [8] [9] A reason for these contrasting findings could be due to the fact that SIRT1 overexpression occurs during development in mOX mice. With this in mind, we generated a mouse model with inducible, muscle-specific overexpression of SIRT1 (i-mOX), thus allowing temporal induction of SIRT1 overexpression in fully developed, adult skeletal muscle. We hypothesized that temporally induction of SIRT1 overexpression in adult muscle would enhance muscle insulin sensitivity and mitochondrial function.
Results

Mouse model
Relative Sirt1 transcript levels were~280-fold higher in skeletal muscle from i-mOX compared to WT mice, while Sirt3 mRNA levels were unchanged (Fig. 1a) . Similarly, SIRT1 protein levels were increased approx. 50-fold in i-mOX vs. WT muscle; the protein levels of the related family members, SIRT3 and SIRT6, were unchanged between genotypes (Fig. 1b,c ). There were no genotype differences in body weight, fat mass or lean mass (Fig. 1d ), nor were there differences in skeletal muscle, (gastrocnemius, tibialis anterior, quadriceps, triceps), heart, liver or epididymal fat pad mass (Table 1) .
Glucose homoeostasis
Fasting blood glucose concentrations were not different between i-mOX, heterozygous (HZ) and WT mice ( Fig. 2a) , nor was the glycemic response to an oral glucose tolerance test (OGTT; Fig. 2b ,c). To assess effects on skeletal muscle insulin sensitivity, we measured ex vivo basal and insulin-stimulated glucose uptake in soleus and extensor digitorum longus (EDL) muscles using a physiological insulin concentration (0.36 nM). While insulin stimulation increased 2-deoxy-glucose uptake (2DOGU) in soleus ( Fig. 2d) and EDL ( Fig. 2e ) above basal, there were no genotype differences in insulin-stimulated 2DOGU (i.e. insulin 2DOGU-basal 2DOGU) in either muscle (Fig. 2d,e ). In line with this, insulin-stimulated phosphorylation of Akt (S473 and T308) and GSK3b (S9) was not different between i-mOX and WT mice (Fig. 2f,g ).
Metabolic proteins in skeletal muscle
Relative transcript abundance of the glucose transporter Slc2a4 (Glut4), and the glycolytic enzymes, hexokinase 2 (Hk2) and pyruvate kinase isoenzyme M1 (Pkm) was significantly lower in i-mOX compared to WT mice, while pyruvate dehydrogenase E1 component subunit alpha (Pdha1) was not different (Fig. 3a) . However, protein levels of GLUT4, HK2, PKM1/2 and PDHa1 in muscle were unchanged between genotypes (Fig. 3b) . Pyruvate dehydrogenase kinase 4 (Pdk4), carnitine O-palmitoyltransferase 1b (Cpt1b) and acyl-CoA dehydrogenase, very long chain (Acadvl) mRNA abundance were similar between genotypes, while transcript levels of acyl-CoA dehydrogenase, long chain (Acadl) were significantly increased in i-mOX compared to WT mice (Fig. 3a) . However, there were no genotype differences for ACADL, ACADVL or fatty acid transporter CD36 protein abundance (Fig. 3c) . Moreover, phosphorylation of AMP-activated protein kinase, alpha (AMPKa) (T172) and downstream target acetyl-CoA carboxylase (ACC) (S79), was similar i-mOX and WT mice (Fig. 3d ).
Whole-body energy expenditure and substrate oxidation
There were no differences in diurnal rhythms of oxygen consumption (Fig. 4a) , carbon dioxide output (Fig. 4b) , respiratory exchange ratio (RER) (Fig. 4c ) and food intake ( Fig. 4d ) between WT and i-mOX mice.
Skeletal muscle mitochondrial markers and function
Relative mRNA expression and protein levels of the transcriptional co-activator PGC-1a were not changed between i-mOX and WT mice (Fig. 5a,b) . In i-mOX compared to WT mice, relative expressions of the mitochondrial electron transport chain components, cytochrome C (Cytc) and succinate dehydrogenase iron-sulphur subunit (Sdhb) were increased, while citrate synthase (Cs) expression was unchanged (Fig. 5c) . At the protein level, however, there were no differences between i-mOX and WT mice for any of the mitochondrial proteins tested; ATP synthase subunit 5 alpha (ATP5A), ubiquinol-cytochrome c reductase core protein 2 (UQCRC2), cytochrome c oxidase I (MTCO1), SDHB, NADH:Ubiquinone oxidoreductase subunit B8 (NDUFB8), cytochrome c oxidase IV (COX4) or CYTC (Fig. 5d,e) . In line with a lack of effect on markers of mitochondrial biogenesis, maximal respiration (as assessed by high-resolution respirometry in isolated muscle fibre bundles) in the presence of malate, octanoylcarnitine, pyruvate, ADP, glutamate and succinate was not different between genotypes (Fig. 5f ).
Muscle fibre area and fibre type
Muscle morphology (Fig. 6a ), muscle fibre cross-sectional area (CSA) and distribution ( Fig. 6b ) and myosin heavy-chain (MyHC) composition (Fig. 6c) were not different between i-mOX and WT mice.
Discussion
SIRT1 activation is a proposed strategy for the treatment of metabolic disorders, such as type 2 diabetes (T2D). 12, 13 Pharmacological activation of SIRT1 improves insulin sensitivity, mitochondrial biogenesis and confers beneficial metabolic effects in animal models of obesity and T2D. [14] [15] [16] However, how SIRT1 regulates these parameters in skeletal muscle is unclear, 17 and there is conflicting evidence on whether activation of SIRT1 in skeletal muscle promotes systemic metabolic effects. 18 For instance, germline overexpression of SIRT1 in muscle does not improve glucose uptake or insulin sensitivity in muscle of young, chow fed or HFD fed mice. 10, 11 Given it is possible that germline activation of SIRT1 in these mice is masking the effect of SIRT1 overexpression in muscle on metabolic parameters, we generated and studied a mouse model that allowed temporal induction of SIRT1 overexpression in adult skeletal muscle (i.e. after development). In line with our previous studies, 10, 11 and other models with SIRT1 overexpression in muscle, 19 temporal overexpression of SIRT1 in adult mice does not affect muscle insulin sensitivity, mitochondrial biogenesis in skeletal muscle, or wholebody energy expenditure. While we did not assess SIRT1 activity in the present study, it is important to note that we 10, 11 and others 20 have previously demonstrated that increased SIRT1 protein abundance in skeletal muscle is closely associated with elevated deacetylase enzyme activity. Importantly, mice with a HZ overexpression of SIRT1 in skeletal muscle do not show any differences in glucose tolerance or skeletal muscle insulin sensitivity compared to WT or i-mOX mice, indicating that dosing of SIRT1 protein levels in muscle does not explain the lack of effect on these parameters. SIRT1 activation by pharmacological activators (i.e. resveratrol, SRT1720) improves glucose homoeostasis and insulin sensitivity in obese rodents and humans. [7] [8] [9] 21 Similar results have been achieved by increasing SIRT1 activity via elevated cellular NAD + levels (i.e.
PARP1/2 inhibition, nicotinamide riboside (NR) supplementation). [22] [23] [24] Likewise, whole body overexpression of SIRT1 protects against ageing-or HFD-induced glucose intolerance in mice. 5, 6, 25 While SIRT1 activation improves glucose homoeostasis in these studies, this effect could be due to improvements in adipose tissue or liver metabolism (or other tissues, such as the pancreas or brain), [26] [27] [28] rather than a direct effect of SIRT1 activation in skeletal muscle. 5, 6 Supporting this notion, the protective effect of SIRT1 gain-of-function during HFD-induced insulin resistance was dependent on suppression of hepatic glucose output, rather than improved glucose disposal. 6 Moreover, the beneficial metabolic effects of whole body overexpression of SIRT1 manifest in mice lacking SIRT1 overexpression in skeletal muscle. 27 Thus, while there are clearly beneficial effects of SIRT1 activation on glucose tolerance, skeletal muscle SIRT1 does not primarily drive these effects. These findings raise an important question; is skeletal muscle the main organ responsible for mediating the beneficial effects of SIRT1 activation on glucose homoeostasis? Apart from skeletal muscle, SIRT1 is highly expressed in other organs important to the regulation of systemic glucose homoeostasis, such as liver, brain and pancreas. 29 Importantly, glucose tolerance in aged or HFD fed mice was improved when SIRT1 was overexpressed specifically in liver, 30 white adipose tissue 31 or pancreatic b-cells. 28 Moreover, systemic glucose tolerance is improved in a mouse model where SIRT1 is overexpressed in adipose tissue and brain, but not in skeletal muscle or liver. 27 Interestingly, a study by Ramadori et al. 26 found that overexpression of SIRT1 in steroidogenic factor 1 (SF1) neurones in the hypothalamus improves skeletal muscle insulin sensitivity. This suggests that central regulation of glucose metabolism could be a mechanism by which pharmacological SIRT1 activation modulates skeletal muscle glucose handling. However, additional studies are required to investigate this aspect further, as a whole brain SIRT1 knockout also improved systemic insulin signalling. 32 Regardless, in the light of our current study, previous results from our laboratory, 10, 11 and studies by others, 6, 27 it is apparent that skeletal muscle SIRT1 is not a primary contributor to systemic glucose metabolism. SIRT1 activates important regulators of mitochondrial biogenesis, such as AMPK 33, 34 and PGC-1a, 35, 36 and is thus considered to be a central regulator of mitochondrial biogenesis. 17, 37 For example, activation of SIRT1 through pharmacological activators or elevated cellular NAD + levels increases skeletal muscle mitochondrial biogenesis. 7, 9, [22] [23] [24] Similarly, mice with a whole-body overexpression of SIRT1 display increased mitochondrial biogenesis and elevated respiration in skeletal muscle. 38 Additionally, muscle-specific overexpression of SIRT1 increased levels of some electron transport chain proteins. 11, 39 In contrast, our results indicate that temporal overexpression of SIRT1 in adult skeletal muscle does not increase whole body metabolic rate, markers of mitochondrial biogenesis or the respiratory capacity of permeabilized muscle fibre bundles. These findings are supported by previous studies in the field, where SIRT1 gain-of-function models showed either no effect 5, 19 or negative effects on mitochondrial biogenesis in skeletal muscle. 20, 40 It is difficult to pinpoint the reason for the discrepancies between these studies, but timing of the SIRT1 overexpression might play a role in the differential response. This is underscored by the fact that constitutive gain-of-function models display elevated markers of mitochondrial biogenesis in muscle, 11, 38 while models with temporal overexpression of SIRT1 for either 1 week, 19 2 weeks 20,40 or 4-6 weeks (this study) do not. Pharmacological activation of SIRT1 also elevates systemic energy expenditure, 8,9 which was not replicated in our study. To us, this indicates that activation of muscle SIRT1 does not directly modulate energy expenditure in sedentary mice, and that such effects seen with pharmacological activation of SIRT1 occur via SIRT1 activation in other tissues. Another explanation could be that 'off-target' effects could mediate the metabolic and mitochondrial outcomes of pharmacological SIRT1-activators. For instance, resveratrol activates AMPK signalling in muscle, 38, 40 which is a nutrient-sensing signalling node important for mitochondrial and metabolic gene transcription. 41 In summary, we demonstrate that temporal overexpression of SIRT1 in skeletal muscle of adult mice does not improve insulin sensitivity or mitochondrial biogenesis in muscle. These findings are in line with our previous studies, 10, 11 and other whole-body models, 6 and support the hypothesis that SIRT1 in skeletal muscle plays a minor role in mediating the beneficial metabolic effects elicited by systemic SIRT1 activation. Thus, it will be of benefit for future studies to elucidate the tissue(s) that contribute to beneficial health effects seen in skeletal muscle as a result of whole-body SIRT1 activation.
Materials and methods
Animals
All studies were conducted on male mice on a C57Bl/ 6 background kept in a conventional facility with a 12-h light/12-h dark cycle. Mice had free access to food and water unless otherwise noted. Inducible, skeletal muscle-specific SIRT1 overexpressing (i-mOX) mice were generated by crossing mice with a tamoxifen (TMX)-inducible Cre recombinase (Cre) expressed under the human a-skeletal actin (HSA) promoter 42 (kindly provided by K. Esser, University of Florida, Gainesville, FL, USA) with mice carrying a floxed stop element upstream of the Sirt1 gene animals and snap frozen in liquid nitrogen. The tibialis anterior muscle was pinned on cork and frozen in liquid-nitrogen cooled isopentane for histological analysis. All experiments were approved by and conducted in accordance with the Animal Care Program at the University of California, San Diego.
OGTT
Fasted (4 h) mice were orally gavaged with 2 g of dextrose per kg body weight, and blood glucose was measured in tail vein blood at 0 (before gavage), 20, 30, 45, 60, 90 and 120 min using a standard handheld glucose metre. Area under the glucose curve (AUC) was calculated using Prism 6 (GraphPad Software Incorporated, La Jolla, CA, USA), and was calculated from baseline (i.e., time '0').
2DOGU
Ex vivo 2-deoxy-glucose uptake (2DOGU) assay was performed as previously described. 11 The insulin concentration for insulin-treated muscles was 0.36 nM (60 lU/ml) (Humulin R; Eli Lilly, Indianapolis, IN, USA). Frozen SOL and EDL muscles were weighed, homogenized and 2DOGU were calculated as previously described. 4 Energy expenditure and body composition
Whole body metabolism was assessed through indirect calorimetry, using the Comprehensive Lab Animals Monitoring System (Columbus Instruments, Columbus, OH, USA). Mice were housed in the CLAMS system for three consecutive days, and whole-body oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), respiratory exchange ratio (RER) and food intake were continuously monitored. The first day was considered acclimatization, and values were averaged for the dark and light phases on day 2 and 3. Body composition was measured using an EchoMRI-100TM analyser (EchoMRI Medical Systems, Houston, TX, USA).
Immunoblotting
Equal amounts of proteins were separated using SDS-PAGE under reducing conditions. Proteins of interest were detected using the following antibodies; SIRT1 (S5196, Sigma-Aldrich, St. Louis, MO, USA 
Respirometry in permeabilized muscle bundles
High-resolution respirometry was performed using an Oroboros O2K Oxygraph (Oroboros Instruments, Innsbruck, Austria), as previously described in, 44 with minor modifications. Fibres from the tibialis anterior muscle were preserved in biopsy preservation solution (BIOPS), and were mechanically separated and permeabilized with 50 mg/ml Saponin for 20 min. Respiratory data were collected at 37°C in hyperoxygenated (200-400 lM) conditions. After normalization of basal respiration in muscle fibre bundles, a substrate-uncoupler-inhibitor titration (SUIT) was performed. Respiration was measured in response to a mixed fatty acid and pyruvate oxidation SUIT (0.5 mM malate + 0.2 mM Octanoylcarnitine (M + Oct), 2.5 mM ADP, 10 lM cytochrome c (CytC), 5 mM pyruvate (Pyr), 10 mM glutamate (Glut), 10 mM succinate (Succ), 1 lM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), 0.5 lM rotenone (Rot) and 2.5 lM Antimycin A (AmA), which were added sequentially and in the order presented. Respiration was normalized to the wet weight of the muscle fibre bundled used.
RNA extraction and RT-PCR
Total RNA was isolated from snap-frozen gastrocnemius muscle using TRIzol Reagent (Thermo Fisher Scientific). RNA concentration was adjusted, and 1 lg of total RNA was used for cDNA synthesis. Semiquantitative real-time PCR analysis was performed using iTaq TM SYBR Green master mix (Bio-Rad) on a CFX384 Touch TM real-time PCR system (Bio-Rad). Relative expression levels for each gene of interest were calculated with the DDC t method, using Tbp as normalization control. Primer sequences used in this study;
Sirt1, 
Histological analysis
Muscle fibre cross-sectional area (CSA) was measured in 10 lm cross-sections cut from the mid-belly of frozen tibialis anterior muscle. Sections were stained using fluorescently labelled wheat germ agglutinin (WGA) to visualize the outlines of muscle fibres. 45 Briefly, muscle sections were fixed in Formalde-Fresh (Thermo Fisher Scientific, Waltham, MA, USA) for 15 min at 37°C, washed in PBS and subsequently incubated with 5 lg/mL Alexa Fluor 488 conjugated WGA (ThermoFisher Scientific) for 10 min. Slides were cover slipped with VECTASHIELD HardSet Antifade Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA). Tile scan images were acquired, and fibre CSAs were counted automatically using a custom-written macro in ImageJ (National Institutes of Health, Bethesda, MD, USA) as described in. 44 Six randomly selected fields were analysed in sections from four mice per genotype, and all experiments were performed in a blinded fashion.
Fibre type
Muscle fibre type was determined in quadriceps by assessment of myosin heavy-chain composition, as previously described.
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Statistics
Data were analysed using an unpaired Student's t-test, 1-or 2-way ANOVA (using repeated measurement when needed), followed by a Tukey's post hoc analysis, with significant differences at P < 0.05. Statistical analyses were performed using Prism 6 (GraphPad Software Incorporated, La Jolla, CA, USA). All data are expressed as mean AE SEM.
